Greece - Buy the Di...
Health Care: Drugs
MAP Pharmaceuticals Inc. (MAPP: NASDAQ)
$15.49 -0.19 | -1.21%
02/09/12 - 04:00 PM ET
88.05K / 113.70K
Vol / Avg. Vol:15.70 / 15.68
Open / Prev. Close:15.44 - 15.80
Today's Range:10.54 - 17.35
52 Wk Range:19.06%
Performance YTD:TheStreet Rating:
Portfolios with MAPP
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- Userrpbatb Portfolio 1
- UserHot Biotech Stocks II
- UserCrankyTrader Random Selection
- UserSMS Portfolio
- UserEd Mahaffey Portfolio - Ble...
- UserWhat would Jesus buy?
- ContributorStockerblog.com Asthma Stocks
- UserInsider Biotech Buys
- Userbruzzzer Portfolio 1
Latest MAPP Headlines from TheStreet
- Play TheStreet's FDA Drug-Approval Contest 01.23.12 | 08:01 am
- 8 Stocks Rising on Unusual Volume 12.19.11 | 12:12 pm
- 27 Hot Drugs Facing FDA Approval in 2012 12.19.11 | 10:12 am
- MAP Pharmaceuticals Inc. Stock Upgraded (MAPP) 11.10.11 | 05:11 am
- Biotech Calendar: 2011-12 FDA Drug Approvals 08.11.11 | 10:08 am
- J.P. Morgan Healthcare Confab: Live Blog 01.11.11 | 04:01 pm
- Movers Roundup: Joy Global, Capital One 09.02.09 | 06:09 pm
- Analyst Says New Levadex Data Could Lift MAP Stock 09.02.09 | 03:09 pm
- BVF Sells $2.4M Worth of Ligand Pharma 06.30.09 | 01:06 pm
- Insider Sells $1.8M Worth of Verifone 06.25.09 | 09:06 am
Press Releases for MAPP
- MAP Pharmaceuticals To Present At Upcoming Investor Conferences - PR Newswire 02.08.12 | 07:02 am
- MAP Pharmaceuticals To Present At The 30th Annual J.P. Morgan Healthcare Conference - PR Newswire 01.04.12 | 07:01 am
- MAP Pharmaceuticals Issued U.S. Patent For Methods Of Achieving Rapid Relief Of Migraine And Minimizing Side Effects Based Upon Pharmacokinetic Profile - PR Newswire 08.11.11 | 07:08 am
- MAP Pharmaceuticals Appoints Frederick H. Graff Vice President, Commercial Operations - PR Newswire 08.09.11 | 07:08 am
- MAP Pharmaceuticals Announces FDA Acceptance For Filing Of NDA For LEVADEX® - PR Newswire 08.02.11 | 07:08 am
- Allergan And MAP Pharmaceuticals Announce Collaboration On LEVADEX™ Investigational Therapy For Acute Migraine - Business Wire 01.31.11 | 08:01 am
- MAP Pharmaceuticals Reports 2009 Fourth Quarter And Year End Financial Results - PR Newswire 03.02.10 | 07:03 am
Partner Headlines for MAPP
- 16 Healthcare Stocks Deeply Discounted From Target Price - Seeking Alpha 01.12.12 | 09:01 am
- 10 Small-Cap Stocks Deeply Undervalued By Target Price - Seeking Alpha 11.11.11 | 10:11 pm
- Allergan Continues at Neutral - Analyst Blog - Zacks 08.29.11 | 10:08 am
